Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma.

Jennifer Jess Kathleen M Sorensen Elissa A Boguslawski Matthew C Stout Zachary B Madaj Benjamin P Caiello Monica Pomaville Elizabeth R Wilson Seneca S Kinn-Gurzo Curtis C Parker Sridhar M Veluvolu Taylor V Brysgel Rebecca S Kaufman Susan M Kitchen-Goosen Jenna M Gedminas Patrick J Grohar

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

These data exploit EWS-FLI1 driven alterations in cell context to broaden the therapeutic window of berzosertib and cisplatin to establish a promising combination therapy and a novel in vivo schedule. See related commentary by Ohmura and Grünewald, p. 3358.

Keyphrases

combination therapy
single cell
stem cells
oxidative stress
mesenchymal stem cells
dna damage
bone marrow
deep learning
drug induced
dna repair